How bad is the market for life science tools companies? If you accept Applied Biosystems’ late March press release at face value, things aren’t looking too good. Revising its forecast for earnings during the quarter ended March 31, the Foster City, Calif.-based analytical instruments company said government funding delays in the US and overseas, as well as “economic uncertainty” linked to turmoil in the Middle East, would lower its earnings for the current quarter and possibly also for the quarter ending June 30.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.